WT1 and acute myeloid leukemia: The objective of this study was to assess the prevalence of WT1 gene overexpression in pediatric patients with AML treated at Children’s Cancer Hospital Egypt (CCHE-57357) on AML protocol adopted from the Children Oncology Group (COG) (NCT01371981) (10) and to evaluate the prognostic significance of WT1 as an MRD marker on survival and disease outcome.